Kathy Ireland to enter cannabidiol consumer products business
Level Brands announced Monday it has entered into a licensing agreement with Vancouver-based Isodiol International to develop Cannabidiol consumer products for kathy ireland Health & Wellness, a licensor to Charlotte, N.C.-based Level Brands, and for Level Brands subsidiary I'M1, the company's lifestyle brand for men.
"Isodiol is an innovative, progressive and pioneering company," stated Kathy Ireland, Level Brands' chairman emeritus and chief brand strategist. "Isodiol's success in CBD products derived from hemp are 99% pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skincare, nano-mist and functional beverages. One of the many responsibilities in this new venture is, for me personally, to serve as educator-in-chief about cannabidiol, and how it is used by Isodiol. This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of [tetrahydrocannabinol, the chemical compound responsible for a euphoric high]. It's ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation."
[quote-from-article] "Level Brands is committed to exploring new and cutting edge technologies and products and bringing them to the American market," noted Martin Sumichrast, Level Brands' CEO. "Isodiol is a pioneer and a leader in the commercialization of a 99% pure, bioactive pharmaceutical grade CBD derived from the hemp plant. We are excited to work with Isodiol on developing the highest quality hemp derivatives-based consumable and topical skin care products for kathy ireland Health & Wellness and I'M1."
"We look forward to benefitting from Kathy Ireland's proven track record in product strategy and marketing," added Marcos Agramont, president Isodiol. "Ms. Ireland has an uncanny sense of her consumers' tastes and needs, which has led to their extraordinary loyalty and confidence in her products. Having brought over 17,000 diverse and popular products to market, she has captured the hearts and minds of millions of customers who actively and consistently support her brands. Ms. Ireland will bring tremendous energy into this burgeoning field, and we are eager to work with her and the incredible team assembled at Level Brands."
The new Isodiol kathy ireland Health & Wellness and I'M1 products are expected to debut in mid to late Spring 2018 and be available online and in select retail stores. Level Brands is committed to social responsibility, with each partner, client and licensee supporting its Millennium Development Goals to improve the condition of lives around the world.
Encore Endeavor One, Level Brands' corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines.
kathy ireland Health & Wellness, I'M1 and EE1 are led in marketing and creative by Stephen Roseberry, president and chief marketing officer of kathy ireland Worldwide, together with that company's global creative director, Jon Carrasco.
Benzer Pharmacy unveils MTM offering
It has been announced by Benzer Pharmacy, that the Tampa- Fla.-based chain will be addressing the demand for clinical solutions to supervise overprescribing patients. The company will be tackling this issue by providing medication therapy management, or MTM, to its customers.
“Medication therapy management is a patient-centric approach to bridge the gap between pharmacists and patients. By providing increased access to pharmacists, patients are able to take on a more active role in their wellness journey,” Alpesh Patel, president of Benzer Pharmacy, said.
The services will include pharmacotherapy consultation, progress check-ins, anticoagulation management, health and wellness programs, immunizations and medication therapy reviews, among others.
“Medication therapy management is a program that helps ensure the patient is adherent with their medications,” Jazz Harvey, CPhT at Benzer Pharmacy, said. “At Benzer Pharmacy an MTM Specialist works alongside pharmacists to ensure the systematic process of collecting patient-specific information, assessing medication therapies to identify medication-related problems, developing a prioritized list of medication-related problems, and creating a plan to resolve them.”
Benzer Pharmacy also will offer comprehensive medication review, or CMR, services to those enrolled in the MTM program. CMR is a systematic process of collecting patient-specific information, assessing medication therapies to identify medication-related problems, developing a prioritized list of medication-related problems, and creating a plan to resolve them with the patient, caregiver and/or prescriber, according to the Centers for Medicare and Medicaid Services.
Those enrolled in the MTM program will have the option to refuse or decline any individual services or disenroll from the service with the company’s CMR offering.
Perrigo names new CEO
Perrigo on Monday announced the appointment of Uwe Röhrhoff as CEO, effective Jan. 15, following the retirement of John Hendrickson.
"I look forward to working with Perrigo's experienced management team, who have been instrumental in positioning the company's consumer OTC and prescription pharmaceutical businesses to capitalize on current trends in the market," Röhrhoff said. "I have long admired Perrigo's operational excellence and its mission to deliver high-quality, affordable healthcare products that improve the lives of patients and families. I see great opportunity to leverage the company's unique asset base and to lead its talented employees to deliver enhanced value for shareholders. Perrigo's core values resonate with me deeply, and I look forward to leading this organization into its next stage of evolution."
"The board of directors is excited to announce the appointment of Uwe as president and CEO," stated Laurie Brlas Perrigo chairman. "Uwe brings a strong track record of operational excellence, strategic growth and healthcare supply chain management. As the CEO of Gerresheimer, a publicly-traded international manufacturer for the global pharmaceutical and healthcare industries, Uwe's transformative strategic vision and focus on operational excellence enhanced the company's leading market positions and created significant value for shareholders of approximately 225% in total shareholder return as CEO. We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo. We are grateful to John for his passionate leadership and contributions to the company over the past 28 years. John has been a trusted leader, a great colleague and a friend to many, and we value his continued guidance as Uwe transitions into his new role."
Röhrhoff has more than 25 years of experience with Gerresheimer, which generated approximately $1.7 billion in revenue in 2016. He began his career with Gerresheimer in 1991, steadily advancing within the organization to serve in a number of key leadership roles in Europe and North America.
Röhrhoff was appointed to build out the company's business in the United States (1996-1998) and head the American subsidiary Gerresheimer Glass (2001-2010). He served as an executive board member (2003-2017), responsible for two of the company's three business units, and CEO (2010-2017) of Gerresheimer until his retirement in August 2017.
Hendrickson will resign as CEO and board member on Jan. 15 and will remain with the company until March 15 to ensure a smooth and successful transition.